Comparative Pharmacology
Head-to-head clinical analysis: DSUVIA versus LERITINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DSUVIA versus LERITINE.
DSUVIA vs LERITINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, high-affinity agonist at the mu-opioid receptor, resulting in analgesia via activation of G-protein coupled inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels in the central nervous system.
LERITINE (anileridine) is a synthetic opioid analgesic that acts as a mu-opioid receptor agonist, modulating pain perception and emotional response to pain.
30 mcg sublingual tablet as a single dose; may repeat once after 1 hour if needed. Maximum 2 doses per 24 hours.
Adults: 25-50 mg orally every 6 hours as needed for pain; not to exceed 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 23.4 hours (range 17–30 h), supporting once-daily dosing. Due to rapid redistribution, clinical effects may wane before elimination is complete.
2-3 hours (terminal half-life in adults; may be prolonged in hepatic impairment or elderly, dosing adjustments recommended)
Primarily renal elimination of metabolites; unchanged drug accounts for <1% of the dose. Fecal excretion is minimal. Total recovery: ~70% in urine, ~20% in feces.
Renal (70-90% as unchanged drug and metabolites); biliary/fecal (10-30%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic